The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk

This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.

NCT Number	NCT07458425
Lead Sponsor	University of Illinois at Chicago
Conditions	Lung Cancer
Enrollment	400 participants
Start Date	2026-03-11
Primary Completion	2027-01 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-06